Afeyan Noubar 的 Form 4 申報
Generate Biomedicines, Inc.（GENB），2026/3/2 申報
- 申報編號
- 0001193125-26-085855
- 申報時間
- 2026/3/2 17:42 ET
- 交易日
- 2026/2/26-3/2
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 8 筆非衍生性交易、11 筆衍生性交易。公開市場買進合計 $7,500 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Afeyan NoubarCIK 0001222012 | 董事、持股 10% 以上大股東 |
| Flagship Pioneering Fund VI, L.P.CIK 0001716926 | 持股 10% 以上大股東 |
| Flagship VentureLabs VI LLCCIK 0001725008 | 持股 10% 以上大股東 |
| Flagship Pioneering Special Opportunities Fund II, L.P.CIK 0001761283 | 持股 10% 以上大股東 |
| Nutritional Health LTP Fund, L.P.CIK 0001780956 | 持股 10% 以上大股東 |
| Flagship Pioneering Fund VII, L.P.CIK 0001805916 | 持股 10% 以上大股東 |
| FPN II, L.P.CIK 0001918834 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/3/2 | Common Stock | C轉換取得 | +12,723,940 | –F1 | – | 12,723,940 | 間接 | |
| 2026/3/2 | Common Stock | C轉換取得 | +13,702,224 | –F1 | – | 13,702,224 | 間接 | |
| 2026/3/2 | Common Stock | C轉換取得 | +987,491 | –F1 | – | 987,491 | 間接 | |
| 2026/3/2 | Common Stock | C轉換取得 | +2,777,752 | –F1 | – | 2,777,752 | 間接 | |
| 2026/3/2 | Common Stock | C轉換取得 | +2,777,752 | –F1 | – | 2,777,752 | 間接 | |
| 2026/3/2 | Common Stock | P買進取得 | +1,562,500 | $16.00 | +$25,000,000 | 15,264,724 | 間接 | |
| 2026/3/2 | Common Stock | P買進取得 | +1,562,500 | $16.00 | +$25,000,000 | 4,340,252 | 間接 | |
| 2026/3/2 | Common Stock | P買進取得 | +1,562,500 | $16.00 | +$25,000,000 | 1,562,500 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/2/26 | Common Stock | A公司授予取得 | +29,561 | $0.00 | $0 | 29,561 | 直接 | 重複申報 |
| 2026/3/2 | Common Stock | C轉換處分 | −12,168,390 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −11,202,248 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −987,491 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −555,550 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −833,325 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −1,944,427 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −1,388,876 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −1,666,651 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −833,325 | $0.00 | $0 | 0 | 間接 | |
| 2026/3/2 | Common Stock | C轉換處分 | −1,388,876 | $0.00 | $0 | 0 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
表 I 有 5 筆交易的價格引用這則附註。
備註
Form 1 of 2: This is the first of two Forms 4 being filed relating to the same event. The Form 4 is being split into two filings because there are more than 10 Reporting Persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 Reporting Persons. Each Form 4 is filed by Designated Filer Noubar Afeyan.